The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.

The stock's fall snapped a two-day winning streak.

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

This was the stock's second consecutive day of gains.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...